101 related articles for article (PubMed ID: 23404192)
1. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
Assoumou L; Descamps D; Yerly S; Dos Santos G; Marcelin AG; Delaugerre C; Morand-Joubert L; Ruffault A; Izopet J; Plantier JC; Pakianather S; Montes B; Chaix ML; Wirden M; Costagliola D; Masquelier B;
J Antimicrob Chemother; 2013 Jun; 68(6):1400-5. PubMed ID: 23404192
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
Assoumou L; Charpentier C; Recordon-Pinson P; Grudé M; Pallier C; Morand-Joubert L; Fafi-Kremer S; Krivine A; Montes B; Ferré V; Bouvier-Alias M; Plantier JC; Izopet J; Trabaud MA; Yerly S; Dufayard J; Alloui C; Courdavault L; Le Guillou-Guillemette H; Maillard A; Amiel C; Vabret A; Roussel C; Vallet S; Guinard J; Mirand A; Beby-Defaux A; Barin F; Allardet-Servent A; Ait-Namane R; Wirden M; Delaugerre C; Calvez V; Chaix ML; Descamps D; Reigadas S;
J Antimicrob Chemother; 2017 Jun; 72(6):1769-1773. PubMed ID: 28333232
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
Masquelier B; Costagliola D; Schmuck A; Cottalorda J; Schneider V; Izopet J; Calvez V; Descamps D; Poggi C; Brun-Vézinet F;
J Med Virol; 2005 Aug; 76(4):441-6. PubMed ID: 15977249
[TBL] [Abstract][Full Text] [Related]
4. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
7. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
8. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
10. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.
Descamps D; Assoumou L; Chaix ML; Chaillon A; Pakianather S; de Rougemont A; Storto A; Dos Santos G; Krivine A; Delaugerre C; Montes B; Izopet J; Charpentier C; Wirden M; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Guinard J; Tamalet C; Cottalorda J; Marcelin AG; Desbois D; Henquell C; Calvez V; Brun-Vézinet F; Masquelier B; Costagliola D;
J Antimicrob Chemother; 2013 Nov; 68(11):2626-31. PubMed ID: 23798669
[TBL] [Abstract][Full Text] [Related]
11. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
12. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
[TBL] [Abstract][Full Text] [Related]
14. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
[TBL] [Abstract][Full Text] [Related]
15. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
Chaix ML; Descamps D; Wirden M; Bocket L; Delaugerre C; Tamalet C; Schneider V; Izopet J; Masquelier B; Rouzioux C; Meyer L; Costagliola D; ; ;
AIDS; 2009 Mar; 23(6):717-24. PubMed ID: 19279445
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
[TBL] [Abstract][Full Text] [Related]
17. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
18. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
20. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
